ArticleBone marrow transplantation2025
Improved outcomes over time in patients aged ≥60 years undergoing allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in first complete remission: a large study by the EBMT acute leukemia working party.
Article in Bone marrow transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Shaping the future of older patients with Philadelphia-negative lymphoblastic leukemia.Haematologica · 2026Article
- Targeting drug efflux and DNA repair enhances inotuzumab ozogamicin activity in IO-resistant B-ALL cell lines.International journal of hematology · 2026Article
- Advances and Controversies in the Management of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Navigating First-Line Therapies.Current hematologic malignancy reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allogeneic hematopoietic cell transplantation remains an important curative treatment for patients with acute lymphoblastic leukemia (ALL). Over time, significant progress in transplant and post-transplant care has allowed the delivery of transplant to older patients. We assessed changes over time in characteristics and outcomes in patients ≥60 years with ALL using a dataset from the EBMT registry. We identified 832 adult patients, with T-cell ALL (n = 143), Philadelphia chromosome positive B-cell ALL (n = 471), or Philadelphia chromosome negative B-cell ALL, transplanted 2010-2022 in first remission irrespective of the donor type. Those included 280 patients transplanted in 2010-2015, and 552 patients transplanted in 2016-2022. Patients transplanted in recent years were slightly older, more likely to have T or Ph- B-ALL and to receive a myeloablative total body irradiation conditioning. The 2-year leukemia free survival (LFS) and overall survival (OS) increased over time from 42-55% and from 51-65%, respectively. In multivariate analysis, LFS, OS, chronic and extensive chronic graft-versus-host disease rates were better in recent years (hazard ratio[HR] 0.68, 0.71, 0.66 and 0.5, respectively). These real-world data can serve as a benchmark indicating that the opportunity for transplant for the fit elderly should be considered and offered when possible.
Indexed as
Identifiers
40437045What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.